Pasniazid Tablets

1. This product is a chemical synthesis of isoniazid (INH) and para-aminosalicylic acid (PAS). INH is mainly effective against mycobacteria in the growth and reproduction period. Its mechanism of action has not yet been elucidated, and it may inhibit the synthesis of mycolic acid (myolic acid) of sensitive bacteria and cause cell wall rupture. 2. PAS effectively delays and blocks the acetylation process of INH in the body. Therefore, this product maintains a higher and longer INH concentration in the blood and reduces toxicity to the liver. After taking equal amounts of INH and this product, it was found that the INH blood concentration was only 0.03 mg/L in 12 hours, but this product was 2.6 mg/L; the INH blood concentration was 0 in 14 hours, but this product was still as high as 2 mg/L, which is twice the MIC. This not only enhances the bactericidal effect of the drug, but also delays the development of bacterial resistance. 3. Clinically confirmed, in combination with other anti-tuberculosis drugs, the anti-tuberculosis efficacy of this product is significantly better than INH, and the incidence of adverse reactions such as gastrointestinal reactions, liver damage and leukopenia is significantly lower than that of INH. 4. Animal experiments show that for artificially infected mice, the anti-tuberculosis efficacy of this product is about 5 times that of INH; the therapeutic effect of this product at 10 mg/kg per day is significantly better than the physical mixed preparation of INH (20 mg/kg per day) and PAS (200 mg/kg per day).

The main ingredient of this product is isoniazid p-aminosalicylic acid.

This product is light yellow tablets or yellow tablets or film-coated tablets.

It is used in combination with other anti-tuberculosis drugs to treat various types of pulmonary tuberculosis, endobronchial tuberculosis and extrapulmonary tuberculosis. It can also be used as a protective drug for tuberculosis-related surgeries, and can also be used to prevent tuberculosis infection and recurrence during long-term or high-dose corticosteroid and immunosuppressive therapy.

1. Treatment: Used in combination with other anti-tuberculosis drugs. Adults: 10-20 mg/kg per day according to body weight. Children: Increase to 20-40 mg/kg per day according to individual needs, taken all at once. 2. Prevention: 10-15 mg/kg per day according to body weight, taken all at once.

Occasionally, adverse reactions such as dizziness, headache, insomnia, fever, rash, nausea, fatigue, jaundice, peripheral neuritis, optic neuritis and hematocytopenia may occur.

1. It is contraindicated for patients with mental illness and epilepsy. 2. It is contraindicated for patients with severe liver dysfunction.

Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: Use with caution in pregnant and lactating women. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.

Not yet clear.

Keep away from light, sealed and stored in a dry place.

0.1g

Tentative 24 months

Guizhou Shenqi Pharmaceutical Co., Ltd.

• Founded in:

  2002-02-28

• Address:

  No. 177, Chuangbei Road, Shawen Ecological Technology Industrial Park, Guiyang National High-tech Industrial Development Zone, Guiyang City, Guizhou Province

• Tax NO.:

  91520000736602733A

• Registered Funds:

  138.71 million yuan

• Website:

  Log in to view

• Email:

  Log in to view